GAGordon Alton

Gordon Alton

*This is an algorithmically generated author record based on publicly available information.

Gordon Alton has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Luigi Longo

    Riverside II Sir John Rogerson’s Quay, San Diego, USA

    2 shared publications
  • Mara Gerloni

    Riverside II Sir John Rogerson’s Quay, San Diego, USA

    2 shared publications
  • Alberto Morisetti

    Toxicology Cronet-SAGL 6900 Lugano Ticino Switzerland

    1 shared publication
  • Ambrosio Lopez

    Center for Innovative Drug Discovery, Department of Chemistry, University of Texas at San Antonio, 1 UTSA Circle, San Antonio, TX 78249, USA

    1 shared publication
  • Ann C.M. Tuma

    Department of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA

    1 shared publication
  • Ashwani Kumar

    Eugene McDermott Center for Human Growth and Development and Department of Pharmacology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA

    1 shared publication

Latest Publications

  • Open Access

    Pharmacologic inhibition of OLIG2 by CT-179 disrupts mitotic progression and enhances standard-of-care chemoradiotherapy in glioblastoma

    by Sam A. Greenall, Shengnan C. Chen, Gordon Alton, Graham Beaton, Reghan Boelter, Mattie Casey, Ivan Babic, Zara C. Bruce, Daniel J. Garama, Rajesh Mukthavaram, et al.

    Background: Glioblastoma (GBM) remains uniformly fatal. The basic helix-loop-helix transcription factor OLIG2 is universally expressed in diffuse glioma, sustains the tumor-propagating stem-like fraction, and opposes p53-mediated genotoxic responses, but has historically been considered undruggable. We characterized CT-179, a brain-penetrant small-molecule OLIG2 inhibitor, as a candidate therapeutic for GBM. Methods: Target engagement was assessed by cellular thermal shift assay, differential scanning fluorimetry, crosslinking, and electrophoretic mobility shift assay. Anti-tumor activity was evaluated across eleven patient-derived GBM cell lines, in zebrafish oligodendrocyte precursor cell (OPC)-derived tumors, and orthotopic and subcutaneous GBM models, including combinations with radiotherapy plus temozolomide and with selective Bcl-2 family inhibitors. Results: CT-179 engaged OLIG2 and altered the conformation of dimerized OLIG2 on chromatin without preventing dimerization or fully displacing OLIG2 from DNA. CT-179 reduced OLIG2-positive OPC’s and OPC-derived tumors in zebrafish and inhibited proliferation across all eleven GBM lines (IC50 < 360 nM), depleting the stem-like fraction and inducing apoptosis through mitotic catastrophe, mitotic slippage, or a hybrid response. RNA-seq across three patient-derived glioma stem cell lines identified β-tubulin gene isoforms as the most strongly CT-179-down-regulated transcripts at the early time point and showed correlated β-tubulin and OLIG2 expression in TCGA glioblastoma specimens. Combination with the Mcl-1 inhibitor S63845 or the Bcl-2/Bcl-xL/Bcl-w inhibitor ABT-737 produced greater-than-additive cytotoxicity. Oral CT-179 crossed the blood-brain barrier and extended median survival as a single agent across two independent adult orthotopic patient-derived backgrounds (GBM8 and G06); intraperitoneal CT-179 was associated with reduced intratumoral OLIG2 and Ki-67 staining in GBM8 orthotopic xenografts. Combination of CT-179 with radiotherapy and temozolomide eliminated all GBM8 and 7 of 8 GBM4 subcutaneous xenografts without weight loss and significantly extended survival when combined with radiotherapy in MGMT-unmethylated GBM6 orthotopic xenografts (CT-179 administered intraperitoneally). Conclusions: CT-179 is a brain-penetrant inhibitor of an established GBM driver with single-agent and combination activity across several orthotopic models, supporting clinical development for GBM and translational evaluation in other OLIG2-dependent CNS malignancies. Key Points: CT-179 is the first brain-penetrant small-molecule inhibitor of OLIG2 with potent activity across patient-derived glioblastoma models. CT-179 induces apoptosis through mitotic catastrophe and slippage rather than collapse of receptor tyrosine kinase signaling. Oral CT-179 combined with radiotherapy and temozolomide eliminates the great majority of subcutaneous patient-derived GBM xenografts without overt toxicity. Oral CT-179 extends single-agent survival across two independent adult orthotopic patient-derived backgrounds (GBM8 and G06); intraperitoneal CT-179 is associated with reduced intratumoral OLIG2 and Ki-67 staining in GBM8 tumors. Intraperitoneal CT-179 plus radiotherapy significantly extends survival in an MGMT-unmethylated GBM6 orthotopic model where temozolomide contributes minimally and supports the rationale for further evaluation in MGMT-unmethylated GBM. Importance of the Study: Glioblastoma is uniformly fatal, and durable disease-modifying therapies that disable the lineage transcription factor programs sustaining the GBM stem-like state have remained elusive. OLIG2 is universally expressed in diffuse glioma and is a central driver of stemness, lineage-restricted RTK signaling, and resistance to genotoxic therapy, yet has historically been considered undruggable. This study reports the foundational preclinical characterization of CT-179, a brain-penetrant small molecule that engages OLIG2 directly and induces glioblastoma cell death through disrupted mitotic progression. Oral CT-179 crosses the blood-brain barrier, prolongs survival in orthotopic patient-derived xenografts, and substantially enhances the efficacy of standard-of-care radiotherapy and temozolomide. Activity in an MGMT-unmethylated orthotopic patient-derived GBM model in combination with radiotherapy is of particular translational interest, since this is the patient population for which temozolomide contributes minimally and the unmet need is greatest. These data establish proof of concept for direct pharmacologic inhibition of OLIG2 in GBM and provide a translational rationale, including an MGMT-stratified combination strategy, for combining CT-179 with current standard-of-care chemoradiotherapy. Lay Summary: Glioblastoma is the most common and aggressive brain cancer in adults, and almost all patients die of their disease. One reason is a protein called OLIG2, which keeps tumor cells in an immature, treatment-resistant state and has long been considered impossible to target with drugs. We studied CT-179, a small molecule that enters the brain and blocks OLIG2. In glioblastoma cells and in mice, CT-179 forced dividing tumor cells into a faulty, lethal division, extended survival on its own, and strengthened the effect of standard radiation and chemotherapy. These results support testing CT-179 in people with glioblastoma.

  • A rifamycin SV in situ gelling formulation for the treatment of pouchitis

    by Katia Mangano, Cinzia Quatrocchi, Katia Ajello, Stefania Pagani, Gordon Alton, Luigi Longo, Mara Gerloni

    Procto-colectomy with an ileal pouch anal anastomosis is performed in Ulcerative Colitis patients as a potential curative surgical option. However, in many patients a non-specific inflammation of the ileal reservoir can occur, named pouchitis. Some patients further develop a chronic antibiotic-resistant disease. Rifaximin, an oral, broad-spectrum antibiotic has been shown to have efficacy for some patients. In the present study CB0125, a novel Rifamycin SV in situ gelling formulation, was developed as a potential pouchitis therapy. This mixture undergoes sol to gel transition under physiological pH and temperature upon administration to the target organ by enema. The in vivo efficacy of the in situ gel was performed using dextran sodium sulphate-induced colitis model in C57/Bl6 mice. The clinical parameters such as body weight changes, rectal bleeding and stool consistency were compared to mesalamine (positive control). In addition, a histopathological investigation was conducted to assess severity of mucosal damage and inflammation infiltrate. CB0125 was well tolerated and there was a significant reduction in disease activity, improved colon weight to length ratio, and improved histology score for the CB-01-25 in situ gel group compared to placebo gel. In addition, CB0125 was superior to mesalamine and to rifamycin SV dissolved in water. We propose that the rifamycin SV in situ gel may provide a longer duration of exposure of this dual acting antibiotic / anti-inflammatory drug at the site of the damaged intestinal mucosa resulting in a superior combined effect, relative to rifamycin SV dissolved in water, for the treatment of pouchitis. Graphical Abstract


  • Open Access

    Genotoxicity and safety profile of Eleview®: A submucosal injectable composition for endoscopic mucosal resection and endoscopic submucosal dissection

    by Luigi Longo, Mara Gerloni, Gordon Alton, Alberto Morisetti

    Background and Objectives: Eleview® submucosal injectable composition with methylene blue (MB), is intended for use in gastrointestinal endoscopic procedures. Given the recognised in vitro mutagenicity of MB, Eleview® mutagenic and genotoxic potentials and its safety profile in acute and subacute toxicity settings were assessed. Methods: Acute and subacute systemic toxicity were tested in rats and dogs, respectively. Ames test and chromosome aberration test in Chinese Hamster V79 cells, were performed. The ratio of polychromatic to normochromatic erythrocytes was assessed in rat bone marrow at the rat MTD. Results: Eleview® oral or intraperitoneal at 20 mL/kg or 50 mL/kg did not induce any acute toxic effects in rats. In dogs, Eleview® (15 mL) did not cause any relevant in-life observations or any histopathological changes in any organs/tissues or injection sites. Ames test demonstrated no concentration-related and reproducible increases in revertant colony numbers. No significant increase of chromosomally aberrant cells was noted in Chinese Hamster cells. Lastly, Eleview® did not elicit significant increase in micronucleated polychromatic erythrocyte frequency. Conclusion: No death or abnormal findings in the acute and subacute studies were observed for Eleview® administration. Eleview® is not genotoxic, nor mutagenic, proving to be a safe medical device to use in clinical practice.